Literature DB >> 9489724

Differential involvement of metabotropic and p75 neurotrophin receptors in effects of nerve growth factor and neurotrophin-3 on cultured Purkinje cell survival.

H T Mount1, S Elkabes, C F Dreyfus, I B Black.   

Abstract

We have examined the role of the p75 neurotrophin receptor in survival-promoting effects of nerve growth factor (NGF) and neurotrophin-3 (NT-3) on cultured Purkinje cells. Previously, we showed that NGF promotes Purkinje cell survival in conjunction with (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (ACPD), an agonist of metabotropic excitatory amino acid receptors, whereas NT-3 by itself increases cell number. We now present evidence that p75 plays different roles in Purkinje cell responses to the two neurotrophins. A metabotropic receptor of the mGluR1 subtype may interact with p75 function, so as to regulate Purkinje cell responsiveness to neurotrophins. When cerebellar cultures were grown for 6 days in the presence of ACPD and a mutant form of NGF that does not bind to p75, no increase in Purkinje cell number was observed. Moreover, the survival-promoting effect of wild-type NGF and ACPD could be inhibited by a neutralizing antiserum to p75 or by a pyrazoloquinazolinone inhibitor of neurotrophin binding to p75. In contrast, the response to NT-3 was potentiated by anti-p75 treatment and by the quinazolinone. These data indicate the mediation of p75 in the trophic response to NGF-ACPD and a negative modulatory role of p75 in the action of NT-3. To probe the role of ACPD in the p75-dependent response to NGF, metabotropic receptor subtype-specific ligands were tested. The pattern of agonist specificity implicated the mGluR1 subtype, a receptor that is expressed at high levels by Purkinje cells and linked to activation of protein kinase C (PKC). Down-regulation or blockade of PKC abolished the response to NGF-ACPD. Consistent with the opposite roles of p75 in effects of the two neurotrophins, blockade of mGluR1 or PKC potentiated the survival response elicited by NT-3. In sum, our data suggest that afferent excitatory transmitters activate specific metabotropic receptors to elicit a p75-mediated action of NGF. NT-3 acts on Purkinje cells by a different mechanism that is not absolutely p75-dependent and that is reduced by neurotrophin access to p75 and metabotropic receptor activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489724     DOI: 10.1046/j.1471-4159.1998.70031045.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Maternal immune activation produces cerebellar hyperplasia and alterations in motor and social behaviors in male and female mice.

Authors:  Tooka Aavani; Shadna A Rana; Richard Hawkes; Quentin J Pittman
Journal:  Cerebellum       Date:  2015-10       Impact factor: 3.847

2.  Neurotrophins induce death of hippocampal neurons via the p75 receptor.

Authors:  W J Friedman
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

3.  The p75 neurotrophin receptor can induce autophagy and death of cerebellar Purkinje neurons.

Authors:  Maria L Florez-McClure; Daniel A Linseman; Charleen T Chu; Phil A Barker; Ron J Bouchard; Shoshona S Le; Tracey A Laessig; Kim A Heidenreich
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

Review 4.  Climbing fiber development: do neurotrophins have a part to play?

Authors:  Rachel M Sherrard; Adrian J Bower
Journal:  Cerebellum       Date:  2002-12       Impact factor: 3.847

5.  Changes in Spontaneous firing patterns of cerebellar Purkinje cells in p75 knockout mice.

Authors:  Jinbin Tian; Chhavy Tep; Michael X Zhu; Sung Ok Yoon
Journal:  Cerebellum       Date:  2013-06       Impact factor: 3.847

6.  The neurotrophin receptor p75NTR mediates early anti-inflammatory effects of estrogen in the forebrain of young adult rats.

Authors:  Vanessa L Nordell; Danielle K Lewis; Shameena Bake; Farida Sohrabji
Journal:  BMC Neurosci       Date:  2005-09-12       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.